Cancer Policy FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies December 05, 2025Vol.51 No.44By Jacquelyn Cobb
Drugs & Targets FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA grants 501(k) clearance for Vanquish System for prostate tissue ablation in intermediate risk prostate cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves durvalumab + FLOT for resectable gastric or gastroesophageal junction adenocarcinoma December 05, 2025Vol.51 No.44
Guest Editorial My introduction to, and lessons learned from, Rick Pazdur November 21, 2025Vol.51 No.43By Mikkael A. Sekeres
Cancer Policy Makary, Prasad describe FDA’s new “plausible mechanism pathway” to get bespoke therapies to market sans RCT November 21, 2025Vol.51 No.43By Jacquelyn Cobb
Drugs & Targets FDA approves Poherdy, first biosimilar to Perjeta, for breast cancer indication November 21, 2025Vol.51 No.43
Drugs & Targets FDA approves epcoritamab-bysp for follicular lymphoma indications November 21, 2025Vol.51 No.43
